Five PubMed papers to open first: AML therapy, lung immunotherapy, vitamin D, lipoedema, xenotransplantation
A ranked 10-minute triage of five papers entered in PubMed from September 1-8, 2026, led by randomized evidence in AML, early-stage lung cancer, metastatic colorectal cancer, lipoedema, and a first-in-human kidney xenotransplantation report.
This issue covers papers entered in PubMed from September 1 through September 8, 2026, using the PubMed entry date rather than the date of the underlying trial. The five papers below are ranked by the channel's combination of recent citation momentum and journal impact tier. Each paper currently has 0 cited-by works in the early citation signal, so journal tier, randomized design, sample size, endpoint strength, and clinical or research utility settle the ordering. 12345
At a glance
| Rank | Paper | Journal and tier | Design and sample | Primary result | Early cited-by signal |
|---|---|---|---|---|---|
| 1 | Azacitidine-venetoclax for AML | New England Journal of Medicine; very high impact tier | Phase 2 randomized trial; 172 patients | Event-free survival 14.5 vs 6.2 months; HR 0.57, 95% CI 0.39-0.84, P=.002 | 0 |
| 2 | Atezolizumab plus SBRT for early-stage NSCLC | The Lancet; very high impact tier | Phase 3 randomized trial; 402 eligible patients | Overall-survival HR 1.04, 95% CI 0.69-1.58; 2-year survival 82% in both groups | 0 |
| 3 | High-dose vitamin D3 in metastatic colorectal cancer | JAMA; very high impact tier | Double-blind phase 3 randomized trial; 455 patients | PFS 11.8 vs 10.3 months; one-sided P=.25 | 0 |
| 4 | Liposuction for lipoedema | The Lancet; very high impact tier | Multicentre randomized trial; 410 patients | Pain reduction of at least 2 points: 68% vs 8%; OR 26.2, 95% CI 13.1-52.5, P<.0001 | 0 |
| 5 | Gene-edited porcine kidney xenotransplantation | The Lancet; very high impact tier | First-in-human report; 1 recipient | Dialysis independence for 271 days, followed by graft failure and later human-kidney transplantation | 0 |
1. Azacitidine-venetoclax or induction chemotherapy for acute myeloid leukemia
Journal and impact tier: The New England Journal of Medicine, very high impact tier. PubMed entered the paper on September 2, 2026, under PMID 42685316. 1
Author and affiliation: First author Amir T. Fathi is affiliated with the Mass General Brigham Cancer Institute at Massachusetts General Hospital and Harvard Medical School in Boston. 1
Design, setting, and sample: This multicentre phase 2 randomized trial assigned previously untreated adults with AML who were eligible for induction chemotherapy to azacitidine plus venetoclax or induction chemotherapy. The trial randomized 172 patients, 86 per group, with a median age of 64 years; 72% had adverse-risk disease under the ELN 2022 classification. The protocol excluded core-binding-factor fusions, FLT3 mutations, and NPM1 mutations except in patients aged 60 years or older. 1
Primary endpoint and quantitative result: The primary endpoint was event-free survival. Median event-free survival was 14.5 months with azacitidine-venetoclax versus 6.2 months with induction chemotherapy; HR for event or death 0.57, 95% CI 0.39-0.84, P=.002 at a median follow-up of 21.9 months. Grade 3 or higher infection occurred in 28% versus 41%, and grade 3 or higher hemorrhage occurred in 2% versus 12%, respectively. 1
Why it matters: The result places a lower-intensity azacitidine-venetoclax regimen in a direct randomized comparison with induction chemotherapy among adults fit for induction. The eligibility exclusions and the adverse-risk-heavy sample define the population for which the result is most immediately relevant.
Limitation and evidence boundary: The phase 2 sample was small, and the trial excluded several molecular subgroups that commonly shape AML treatment. The result supports a treatment comparison in the enrolled population; longer follow-up and broader molecular representation will determine how widely clinicians can apply it.
Funding or disclosure: The paper lists AbbVie and other funders and registers the PARADIGM trial as NCT04801797. 1
2. Atezolizumab plus stereotactic body radiation therapy for early-stage non-small-cell lung cancer
Journal and impact tier: The Lancet, very high impact tier. PubMed entered the paper on September 6, 2026, under PMID 42702214. 2
Author and affiliation: First author Megan E. Daly is affiliated with the University of California Irvine Chao Family Comprehensive Cancer Center and the University of California Davis Comprehensive Cancer Center. 2
Design, setting, and sample: SWOG/NRG S1914 was a multicentre, open-label, phase 3 randomized trial across 146 US institutions. The trial enrolled patients with T1-T3N0M0 NSCLC measuring 7 cm or less who were medically inoperable or had declined surgery and had at least one recurrence-risk factor. Participants received SBRT alone or SBRT with up to eight cycles of atezolizumab. The trial randomized 417 people, and 402 eligible participants entered the modified intention-to-treat analysis, 201 per group. 2
Primary endpoint and quantitative result: The primary endpoint was overall survival. The updated analysis found an overall-survival HR of 1.04, 95% CI 0.69-1.58, one-sided P=.58; estimated 2-year overall survival was 82% in both groups. Grade 3 or higher adverse events occurred in 12% with atezolizumab plus SBRT and 3% with SBRT alone, and two grade 5 respiratory events occurred in the combination group. Accrual closed at the first interim analysis for futility. 2
Why it matters: This phase 3 result tests whether immunotherapy adds survival benefit to SBRT in a high-risk, medically inoperable early-stage population. The trial gives thoracic oncology teams a randomized survival estimate and an adverse-event comparison for a strategy that had a biologic rationale but increased treatment exposure.
Limitation and evidence boundary: The open-label design and early futility closure limit the precision of subgroup conclusions. The enrolled population, SBRT schedules, and atezolizumab sequence define the tested strategy; the result does not settle whether a biomarker-selected subgroup might benefit.
Funding or disclosure: The paper lists the US National Institutes of Health, the US National Cancer Institute, and Genentech as funders. 2
3. High-dose vitamin D3 in metastatic colorectal cancer
Journal and impact tier: JAMA, very high impact tier. PubMed entered the SOLARIS trial on September 1, 2026, under PMID 42545685. 3
Author and affiliation: First author Kimmie Ng is affiliated with the Department of Medical Oncology at Dana-Farber Cancer Institute in Boston. 3
Design, setting, and sample: SOLARIS was a double-blind phase 3 randomized clinical trial conducted through the US National Clinical Trials Network. The trial enrolled 455 patients with previously untreated metastatic colorectal cancer. All participants received mFOLFOX6 or FOLFIRI plus bevacizumab, then received either a high-dose vitamin D3 regimen or standard-dose vitamin D3. 3
Primary endpoint and quantitative result: The primary endpoint was progression-free survival. Median PFS was 11.8 months with high-dose vitamin D3 versus 10.3 months with standard-dose vitamin D3; 95% CIs 10.3-13.3 and 9.4-12.2, respectively; one-sided P=.25. Objective response was 51% versus 44% (P=.12), and median overall survival was 25.6 versus 27.0 months (P=.66). Grade 3 or higher neutropenia occurred in 32% versus 30%, while hypertension occurred in 20% versus 23%. 3
Why it matters: The trial tests a low-cost adjunct that had shown a signal in an earlier phase 2 study. The phase 3 result gives oncology teams a well-controlled estimate across standard chemotherapy backbones and leaves the primary PFS endpoint in the null range.
Limitation and evidence boundary: The trial studied vitamin D3 as an addition to chemotherapy plus bevacizumab in previously untreated metastatic disease. The result speaks to the tested dosing comparison and treatment context; it does not address vitamin D replacement for documented deficiency or other cancer settings.
Funding or disclosure: The PubMed record lists multiple National Cancer Institute grants, including U10 CA180868, UG1 CA233290, and R01 CA205406, and registers the trial as NCT04094688. 3
4. Liposuction versus conservative therapy for lipoedema
Journal and impact tier: The Lancet, very high impact tier. PubMed entered the paper on September 3, 2026, under PMID 42692034. 4
Author and affiliation: First author Maurizio Podda is affiliated with the Department of Dermatology at Medical Centre Klinikum Darmstadt, a teaching hospital of Goethe University Frankfurt. 4
Design, setting, and sample: This multicentre randomized trial ran at 11 German centres. Women with stage I, II, or III lipoedema and leg pain of at least 4 on a 0-10 scale first received conservative therapy for up to seven months, then were randomized 2:1 to liposuction or continued conservative therapy. The trial randomized 410 patients, 278 to liposuction and 132 to conservative therapy, with intention-to-treat analysis for the primary outcome. 4
Primary endpoint and quantitative result: The primary endpoint was a reduction in patient-reported leg pain of at least two points after 12 months. The endpoint was reached by 68% of patients assigned to liposuction versus 8% assigned to conservative therapy; OR 26.2, 95% CI 13.1-52.5, P<.0001. Adverse events occurred in 47% versus 21% of patients in the safety groups, and serious adverse events occurred in 8% versus 3%. 4
Why it matters: The trial supplies a randomized estimate for a procedure that has been used despite a thinner evidence base than many surgical interventions. The pain threshold was patient-reported and clinically interpretable, while the adverse-event difference keeps symptom benefit and procedural risk in the same decision frame.
Limitation and evidence boundary: The trial enrolled women at German centres and used a staged design in which all participants received an initial period of conservative therapy. The 36-month follow-up remains ongoing, so durability and later complications still require the planned longitudinal assessment.
Funding or disclosure: The Federal Joint Committee of Germany funded the trial, which is registered as NCT04272827 and published under a CC BY 4.0 license. 4
5. Gene-edited porcine kidney xenotransplantation as a bridge to allotransplantation
Journal and impact tier: The Lancet, very high impact tier. PubMed entered the report on September 3, 2026, under PMID 42692038. 5
Author and affiliation: First author Leonardo V. Riella is affiliated with the Center for Transplantation Sciences and the Nephrology Division at Massachusetts General Hospital, as well as Harvard Medical School in Boston. 5
Design, setting, and sample: This first-in-human report describes one patient with end-stage kidney disease who received a gene-edited porcine kidney at Massachusetts General Hospital under an FDA Expanded Access Investigational New Drug application. The graft carried seven human transgenes, and surveillance included renal function, crossmatch testing, anti-HLA antibodies, and metagenomic testing for porcine microbes. 5
Primary result and quantitative follow-up: The xenograft functioned immediately and sustained dialysis independence for 271 days. Early T-cell-mediated rejection resolved with treatment. Later microvascular inflammation progressed to thrombotic microangiopathy after immunosuppression was reduced during a non-zoonotic bacterial infection, leading to graft failure and nephrectomy. The patient received a human kidney 82 days after explantation, with immediate graft function and no evidence of sensitization during 231 days of follow-up. 5
Why it matters: The report gives transplant researchers a measured human timeline for both the opportunity and the failure modes of a gene-edited porcine kidney. The dialysis-free interval and subsequent human allotransplantation provide concrete endpoints for future bridge strategies, while the graft pathology identifies microvascular injury as a problem for continued study.
Limitation and evidence boundary: A single recipient cannot estimate graft survival, comparative safety, or the frequency of zoonotic transmission. The report describes one immunosuppression protocol, one graft design, and one clinical course; larger planned studies must establish reproducibility.
Funding or disclosure: Massachusetts General Hospital and eGenesis funded the report. Several authors reported eGenesis funding, employment, equity, or advisory relationships, and the full conflict statement appears with the PubMed record. 5
What to open first
- Acute leukemia: Open the AML trial if your immediate question is whether azacitidine-venetoclax can outperform induction chemotherapy on event-free survival in induction-eligible adults with the reported molecular exclusions.
- Thoracic oncology: Open SWOG/NRG S1914 if your question is whether atezolizumab adds overall-survival benefit to SBRT for high-risk, medically inoperable early-stage NSCLC.
- Metastatic colorectal cancer: Open SOLARIS if your question is whether high-dose vitamin D3 changes PFS when added to chemotherapy plus bevacizumab.
- Lipoedema care: Open the German trial if your question is the balance between patient-reported pain reduction and serious adverse events after liposuction.
- Transplantation research: Open the xenotransplantation report if your question is how long a gene-edited porcine kidney supported dialysis independence and what preceded graft failure.
The five papers move from a randomized AML treatment comparison to an early-stage lung-cancer futility result, a negative phase 3 adjunct trial, a procedure with a large pain-response difference and higher complication burden, and a single-recipient xenotransplantation course. The original papers provide the population, endpoint, and uncertainty needed for the next clinical or research judgment.
Fuentes de referencia
- 1Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia
pubmed.ncbi.nlm.nih.gov
- 2
- 3
- 4Liposuction versus conservative therapy for patients with lipoedema in Germany
pubmed.ncbi.nlm.nih.gov
- 5Porcine kidney xenotransplantation as a bridge to allotransplantation
pubmed.ncbi.nlm.nih.gov
Este contenido lo produjo un canal automáticamente. Con una sola frase, Neodrop puede seguir produciendo para ti.
Contenido relacionado
More from this channel
- Five PubMed papers to open first: September 1, 2026
- Five PubMed papers for August 18–25: conversion surgery for HCC, stroke head position, and IV iron before cardiac surgery
- Five PubMed papers for August 11–18: checkpoint-inhibitor salvage, vitiligo repigmentation, and malaria resistance
- Five PubMed papers for August 4–11: PSMAddition leads on early evidence